Filter By
- Agency-Based Community Benefit (ABCB)
- Behavioral Health Reform and Investment Act Senate Bill 3 (SB3)
- Beneficiary Advisory Council (BAC)
- Child Support Services
- DDSD Provider Enrollment & Relations
- Electronic Benefits Transfer (EBT)
- Employee Abuse Registry (EAR)
- Fraud, Waste, & Abuse
- Health Care Consolidation Oversight Act
- Intermediate Care Facility for Individuals with Intellectual Disabilities (ICF/IID)
- (-) Justice-involved Utilization of State Transitioned Healthcare (JUST Health)
- Marketplace Affordability Programs
- Medicaid Transition Premium Relief Program
- National Guard Premium Assistance
- New Mexico Medicaid Estate Recovery Program
- Ordering, Referring, Prescribing Provider (ORP)
- Refugee Resettlement Program
- Rural Health Care Delivery Fund
- Small Business Health Insurance Premium Relief Initiative
- SNAP Quality Control Reviews
- State Employee Premium Assistance Program
- Sun Bucks
- Supplemental Nutrition Assistance Program (SNAP)
- (-) Turquoise Care
Facilities are expected to provide medications in-hand upon release for individuals with stays longer than 48 hours, and who have been clinically evaluated and prescribed a medication.
In cases where the detainee is released before they have been medically evaluated, or so soon after their medical evaluation that it is impossible to obtain any medications that they have been prescribed, facilities are expected to provide an electronic prescription to a community pharmacy and/or coordinate with the MCO or community provider to ensure the prescription is filled. In this scenario, the facility must document the reason the medications were not provided in-hand at the time of release (i.e., due to an unexpected release or very short stay).
Yes, facilities are expected to order medications (as clinically appropriate based on a medical evaluation) as soon as feasible upon intake/incarceration to mitigate the challenge of an unexpected release. If medications ordered were not yet dispensed by the pharmacy, the pharmacy may be able to reverse the Medicaid claim, depending on the pharmacy arrangement. The detention facility should refuse the delivery of medications if the individual has left the facility. If delivery is accepted by a facility after the individual has left, the facility should work with the dispensing pharmacy to determine whether and how medications should be destroyed.
Facilities are expected to make every effort to provide the medications in-hand as the individual leaves the carceral facility. Transportation should not be the primary solution to address this requirement as transportation or delivery may result in gaps due to pharmacy operating hours, member refusal, etc. Facilities can provide transportation to the pharmacy or coordinate delivery of medications to the facility as a mitigation strategy. If medications cannot be provided at the time of release and the member is enrolled in an MCO, the facility may coordinate directly with the member’s MCO to arrange transportation to a pharmacy for prescription pickup. Transportation for this purpose is a covered MCO service for up to seven days following release.
JUST Health Plus covers induction and maintenance of MAT. Providing only maintenance is allowable under the 1115 demonstration (JUST Health Plus) as facilities ramp-up MAT capacity, but the goal is to provide induction of MAT as is feasible.
Long-acting injectable MAT (e.g., Buprenorphine) is covered by Medicaid and therefore reimbursable under JUST Health Plus. All MAT drugs are preferred regardless of brand. Please refer to the Preferred Drug List (PDL).
MAT medications, up to a 30-day supply, must be provided in-hand upon release as clinically appropriate. HCA expects prescribers to use their clinical judgement when determining the appropriate amount of medication to provide upon release. The provision of long-acting injectable MAT prior to release may fulfill the requirement for the (up to) 30-day supply of medications upon release.
JUST Health Plus covers initiation and maintenance of HepC treatment under Service Level 2. Providing maintenance of HepC treatment is allowable under the 1115 demonstration (JUST Health Plus) as facilities ramp-up treatment capacity, but the goal is to test and treat HepC as clinically appropriate. Facilities are expected to offer treatment when testing for HepC (as clinically indicated).